Merck & Co., Inc. (MRK) is
not a hot stock in the stock market
today because the stock market news
in the biotech and pharmaceutical industry is focused on small cap
biopharmaceutical stocks. Here at Bidness Etc we have recommended a hold on
Merck for several reasons of which the most important is its blockbuster drug MK-3475 is to gain
approval later this year.
Another investment
strategy regarding Merck would be to buy
the stock prior to the news of a potential sale of the company’s consumer care segment or the spinoff of its animal health segment. The pharmaceutical industry has seen big players like Pfizer Inc, (PFE) and Abbot Laboratories (ABT) adopt these strategies and have added tremendous value to its investors.
the stock prior to the news of a potential sale of the company’s consumer care segment or the spinoff of its animal health segment. The pharmaceutical industry has seen big players like Pfizer Inc, (PFE) and Abbot Laboratories (ABT) adopt these strategies and have added tremendous value to its investors.
Merck has been a good financial
investment for those looking for a high
dividend stock as the company has a dividend yield 3.17%. Since 2010 the
company has been consistently raising their dividends per share while also
repurchasing shares with currently a $15 billion share repurchase program being
exercised.
The company’s global reach and multiple drugs
with blockbuster potential in its pipeline it is a company to invest in by the end of the first half of 2014. Offering
free stock market investment tips
along with free industry analysis of
the pharmaceutical industry, Bidness Etc is bullish on the biotech and
biopharmaceutical industry.
No comments:
Post a Comment